Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Immuta Delivers a Breakthrough in Automated Data Governance: Compliant Data Collaboration

Published

on

Reading Time: 4 minutes

COLLEGE PARK, Md.–(BUSINESS WIRE)–Immuta
today announced an industry first: No-code, automated governance
features that enable business analysts and data scientists to securely
share and collaborate with data, dashboards, and scripts without fear of
violating data policy and industry regulations. The Immuta platform
ensures compliance with all major data regulations – including the
General Data Protection Regulation (GDPR), The California Consumer
Privacy Act (CCPA), and the Health Insurance Portability and
Accountability Act (HIPAA).

According to Gartner, Inc.’s Risk Management Leadership Council’s April
2019 Emerging
Risks Monitor Report
, “Accelerating Privacy Regulation” is the
number one concern among risk, audit, and compliance executives. As
defined by Gartner, “Accelerating Privacy Regulation” is “the risk of
progressively complicated statutory regimes, which cover the use and
protection of customer data, creating the potential for legal and
financial exposure,” e.g. GDPR, CCPA, and HIPAA.

The Immuta Automated Data Governance Platform creates trust across
security, legal, compliance and business teams so they can work together
to ensure timely access to critical business data with minimal risks.
Its automated, scalable, no code approach makes it easy for users across
an organization to access the data they need on demand, while protecting
privacy and enforcing regulatory policies on all data.

New compliant collaboration features include:

Automated Policy Inheritance
Historically, data policies
have been managed at the application or system level. When analysts
attempt to integrate data across many disparate systems, it can be
difficult, if not impossible, to re-write these rules into a new,
combined policy. This process is slow, complex, error-prone, and
requires months of calls, emails, and meetings. Immuta’s new Automated
Policy Inheritance feature eliminates the need for human intervention to
manage policies across mashed up data sources. Analysts can
instantaneously and securely create integrated data sources, share
derived data from them and collaborate across the organization – with
confidence that the proper controls are in place.

Watch this
video
to learn more.

Re-Identification Requests: On-Demand De-Masking of Sensitive Data
Gaining
authorization for viewing regulated data – especially when it’s a single
piece of data such as a name, email or phone number – can be confusing
and cumbersome. Most organizations still use slow, poorly documented
processes for sensitive data requests. This creates significant barriers
for time sensitive, ‘need to know’ data access requests.

For example, imagine a situation where a researcher uncovers a medical
misdiagnosis in a set of healthcare data. Knowing how to request and
re-identify that person and their contact information, in a timely
manner, without breaking the privacy of others, could save that person’s
life while maintaining the highest of ethical standards.

To remove the complexity and confusion involved with consent, Immuta has
introduced Format Preserving Encryption and Reversible Masking features
so that users can immediately place a digital request for the data that
they need to be “de-masked,” eliminating chaos and confusion. Digital
requests are instantaneously presented for authorization so that
decisions on sensitive data access can be done quickly and securely –
allowing an immediate, one-time re-identification for the requested
data, or elevating the request for additional scrutiny.

Watch this
video
to learn more.

Fingerprints: Capture the Impact of Data Policy Changes on Downstream
Data Users

When a data owner needs to make access and control
policy changes to a data source, there has never been a way to
demonstrate the impact those changes could have on the downstream use of
that data. For example, statistical changes to data used within
analytics or dashboards could have a major impact on the accuracy of a
model or the integrity of business intelligence dashboards.

The new Immuta Fingerprints feature eliminates any uncertainty about how
downstream use could be impacted. It calculates the impact of data
policy changes and provides visualizations to users of the statistical
deviation. Together, with the Immuta Policy Inheritance feature,
downstream users are notified about any changes and are provided details
on how their use of the impacted data will affect them.

Watch this
video
to learn more.

Immuta also announced today that its platform is now interoperable with
the Databricks Spark analytics engine, and cloud-based data warehouses
Google Big Query and Snowflake.

Register here
for a webinar on Wednesday, May 15 at 2:00 p.m. ET in which Steve Touw,
Immuta co-founder and CTO, will conduct a live demo of the Immuta
Automated Data Governance Platform.

Halim Abbas, Chief AI Officer, Cognoa
“With
Immuta’s new re-identification feature, it is now possible for our data
analysts to identify outliers in anonymized datasets, and start a
well-controlled workflow to mark those specific samples to an authorized
admin for de-anonymized investigation in a way that fully conforms with
health industry data-privacy guidelines.”

Steve Touw, Co-founder and Chief Technology Officer, Immuta
“Immuta
has delivered another industry first: workflow features that allow users
to confidently and securely collaborate with sensitive data across their
organization because they know, through the Immuta platform, that the
rules will be enforced. They also have the freedom to make changes on
the fly without any concern that privacy policies will be infringed
upon. Also, if a policy needs to be changed, we’ve made it easy for the
user to go through the workflow and adapt as needed.”

Additional Resources:

About Immuta
Immuta was founded in 2014 based on a mission
within the U.S. Intelligence Community to build a platform that
accelerates self-service access and control of sensitive data. The
award-winning Immuta Automated Data Governance Platform creates trust
across security, legal, compliance, and business teams so they can work
together to ensure timely access to critical business data with minimal
risks. Its automated, scalable, no code approach makes it easy for users
to access the data they need, when they need it, while protecting
sensitive data and ensuring their customers’ privacy. Immuta is
headquartered in College Park, Maryland. Learn more at www.immuta.com.

Contacts

Media
Whitney Parker
[email protected]
617-986-5000


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect

Published

on

Continue Reading

Cannabis

Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand

Published

on

Continue Reading

transfer

IMC to transfer its Oranim Pharmacy shares back to the seller

Published

on

imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller

TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the  seller.

“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to,  the occurrence of growth opportunities and the likelihood of growth potential.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.

The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contacts:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania